ClinicalTrials.gg
CompletedNCT03340064PEACHUpdated Jul 23, 2024Results posted

A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age

A Phase 3 interventional study of Levetiracetam in Partial Seizures, sponsored by UCB Japan Co. Ltd.. Completed at 21 sites in Japan. Open to participants aged 1 Month to 3 Years. Per ClinicalTrials.gov, last updated 2024-07-23.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
1 Month to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies testing levetiracetam in Seizures — 9 open to participants now, 9 under way, 5 of them phase 3. Levetiracetam · Seizures.

Enrollment
35th of 52
38 · median 68
Started
2017
with 2 others
Phase 3
19 of 52
5 open now
Registered
40th of 52
by date
Lead sponsor
4 of 52
UCB Japan Co. Ltd.

Among the 52 studies testing levetiracetam in Seizures, this one is the 35th largest by enrollment, is one of 3 that started in 2017, is one of 19 in phase 3, and was the 40th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

9 of the 52 studies testing levetiracetam in Seizures are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 1 Month to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing levetiracetam in Seizures, or all of them as a file.
02

Study summary

This is a study to confirm the efficacy of levetiracetam as adjunctive treatment or as monotherapy in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.

Read the detailed description

The study will consist of 2 periods. The First Period (6 weeks drug treatment) is designed to confirm efficacy of levetiracetam (LEV), and the Second Period is designed to evaluate the long-term efficacy and safety of LEV.

03

Conditions studied

  • Partial Seizures

Keywords

  • Epilepsy
  • Partial Seizures
  • Levetiracetam
  • Monotherapy
  • Adjunctive Treatment
04

Who can participate

Ages eligible
1 Month to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have a diagnosis of epilepsy with partial onset seizures whether or not secondarily generalized
  • Male or female from 1 month to \<4 years of age. Pre-term infants aged \<1 year are to be stratified into an appropriate age category using the best estimate of their corrected gestational age
  • For subjects on adjunctive therapy, subject must be on a stable antiepileptic drug (AED) regimen for the Selection and Evaluation Periods of the study. Minor adjustments to the dose of current AEDs are allowed only prior to Visit 1. Monotherapy subjects must not receive AED treatment, receive temporary AED treatment, or switch an AED prior to Visit 1
  • Subject weighs >=3.0 kg
  • Subject may have Vagal Nerve Stimulation (VNS) which has been implanted for at least 6 months prior to Visit 1; the settings must be stable for at least 2 months prior to Visit 1. Activated VNS must be counted as 1 of the 2 AEDs
  • Subject must have experienced at least 2 observable partial seizures, with or without secondary generalization during each 7-day period during the 2 weeks prior to Visit 1. This time period (the 2 weeks prior to Visit 1) will be referred to as the Retrospective Baseline Period. This seizure information (including type, frequency, and date) must have been recorded on a daily record card (DRC) in order to be acceptable
  • If epilepsy surgery has been performed prior to study entry, subjects must have a documented failed epilepsy surgery outcome at least 4 weeks prior to Visit 1
  • The use of intermittent benzodiazepines, phenobarbitals, and phenytoins is allowed as long as the frequency is not greater than 1 single administration per week for at least 2 weeks prior to Visit 1 and throughout study participation. If benzodiazepines are used more than once a week, they must be considered as 1 of the AEDs

Exclusion criteria

Exclusion Criteria:

  • Subject has been taking any medication (other than their concomitant AEDs) that influences the central nervous system (CNS) for which they had not been on a stable regimen for at least 1 month prior to Visit 1
  • Subject is taking any medication that may interfere with the absorption, distribution, metabolism, or excretion of the concomitant AEDs or levetiracetam (LEV) during the course of the study
  • Subject has received any medication or device within 30 days prior to Visit 1
  • Subject has taken LEV prior to the study
  • Subjects using felbamate who have presented with abnormalities and/or hepatic function during felbamate treatment, and subjects who are taking felbamate \<1year from the date of Visit 1
  • History of status epilepticus requiring hospitalization during the 30 days prior to Visit 1, except for status epilepticus occurring during the first 10 days of life
  • Subject has a treatable seizure etiology
  • Subject is on a ketogenic diet (concomitantly or within 30 days prior to Visit 1)
  • Subject has epilepsy secondary to progressing cerebral diseases
  • Subject has a current diagnosis of Rasmussen's syndrome, Landau-Kleffner disease or Lennox-Gastaut syndrome
  • Clinically significant deviations from reference range values for renal function or any of the other laboratory parameters required for this study, as determined by the Investigator
  • Clinically significant acute or chronic illness (as determined during the physical examination or from other information available to the Investigator)
  • Allergy to pyrrolidine derivatives or a history of multiple drug allergies
  • Subject is known to have a terminal illness
  • Subject has a disorder or condition that may interfere with the absorption, distribution, metabolism, or excretion of medications
  • Subject has a history of or presence of pseudoseizures
  • Subject has any medical condition that might interfere with the subject's study participation
  • Subject has ≥3x (ULN) of any of the following: (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \<35%)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Subjects aged 1 month to \<6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to \<6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to \<4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day. At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to \<6 months or by LEV 20 mg/kg/day for subjects aged 6 months to \<4 years at 2-week intervals to 0 mg/kg/day.

    Drug: Levetiracetam

Interventions

  • levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)

    Also known as: Keppra, E-Keppra, LEV

06

What researchers measure

Primary outcomes

  1. Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6

    The percent difference in partial seizure frequency per week at Baseline and Study Visit 6 (Week 6) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 6)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.

    Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)

Secondary outcomes

  1. Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 4

    The percent difference in partial seizure frequency per week at Baseline and Study Visit 4 (Week 2) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 4)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.

    Time frame: From Baseline (Week 0) to Visit 4 (up to Week 2)

  2. Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 5

    The percent difference in partial seizure frequency per week at Baseline and Study Visit 5 (Week 4) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 5)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.

    Time frame: From Baseline (Week 0) to Visit 5 (up to Week 4)

  3. Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy

    Percent difference in partial seizure frequency (PSF) per week at each Analysis Visit: {\[(Number of partial seizures per week at Baseline \[BL\]) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Positive value indicates reduction in PSF from BL. End of study (EOS)/early discontinuation visit (EDV) was based on last EDV and calculation of number of partial seizure per week were based on the period from the previous EDV visit. The mapping of seizure data to Analysis Visits was based on target dates of the visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to the next Analysis Visit (n+1). Data for one participant assessed within study duration was mapped to Analysis Visit 35/Week 300 based on statistical plan.

    Time frame: From Baseline (Week 0), Week 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV (up to Week 295), and Safety follow-up (up to Week 295)

  4. Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy

    Percent difference in PSF per week on adjunctive therapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PSF per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. Positive value in percent difference from Baseline indicates reduction in PSF from Baseline. The mapping of seizure data to Analysis Visits was based on target dates of visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to next Analysis Visit (n+1).

    Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV Week 2, EOS/EDV Week 4, and Safety follow-up (up to Week 295)

  5. Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy

    The percent difference in partial seizure frequency per week on monotherapy at Baseline and each analysis visit was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at analysis visit X)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. The maximum duration of study participation in monotherapy participants was shorter than in adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.

    Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295)

  6. Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy

    Percent difference in PSF per week on monotherapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PFS per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. Maximum duration of study participation in monotherapy participants was shorter than adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.

    Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295)

  7. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation Participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The treatment-emergent adverse events (TEAEs) were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.

    Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)

  8. Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period

    A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.

    Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)

  9. Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.

    Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)

  10. Percentage of Participants With TEAEs During the Combined First and Second Period

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.

    Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)

  11. Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period

    A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.

    Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)

  12. Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period

    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.

    Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)

07

Results

Posted Jul 23, 2024

Participant flow

The study started to enroll participants in November 2017 and concluded in July 2023.

First Period
Participant flow — First Period
MilestoneLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
Started326
Completed276
Not completed50
Withdrew: Adverse event, non-fatal20
Withdrew: Lack of efficacy30
Second Period
Participant flow — Second Period
MilestoneLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
Started276
Completed84
Not completed192
Withdrew: Adverse event, non-fatal11
Withdrew: Lack of efficacy110
Withdrew: Physician decision30
Withdrew: Withdrawal by subject21
Withdrew: Approved drug available for indication10
Withdrew: Protocol-specified withdrawal criterion met10

Outcome measures

PrimaryPercent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6

The percent difference in partial seizure frequency per week at Baseline and Study Visit 6 (Week 6) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 6)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.

Time frame:
From Baseline (Week 0) to Visit 6 (up to Week 6)
Reported as:
Median · percent change
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6
percent changeLevetiracetam: Adjunctive Therapy
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 624.24 (-25.48 to 51.85)
SecondaryPercent Change in Partial Seizure Frequency Per Week From Baseline to Visit 4

The percent difference in partial seizure frequency per week at Baseline and Study Visit 4 (Week 2) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 4)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.

Time frame:
From Baseline (Week 0) to Visit 4 (up to Week 2)
Reported as:
Median · percent change
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 4
percent changeLevetiracetam: Adjunctive Therapy
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 48.62 (-343.1 to 100.0)
SecondaryPercent Change in Partial Seizure Frequency Per Week From Baseline to Visit 5

The percent difference in partial seizure frequency per week at Baseline and Study Visit 5 (Week 4) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 5)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.

Time frame:
From Baseline (Week 0) to Visit 5 (up to Week 4)
Reported as:
Median · percent change
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 5
percent changeLevetiracetam: Adjunctive Therapy
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 516.79 (-414.3 to 100.0)
SecondaryPercent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy

Percent difference in partial seizure frequency (PSF) per week at each Analysis Visit: {\[(Number of partial seizures per week at Baseline \[BL\]) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Positive value indicates reduction in PSF from BL. End of study (EOS)/early discontinuation visit (EDV) was based on last EDV and calculation of number of partial seizure per week were based on the period from the previous EDV visit. The mapping of seizure data to Analysis Visits was based on target dates of the visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to the next Analysis Visit (n+1). Data for one participant assessed within study duration was mapped to Analysis Visit 35/Week 300 based on statistical plan.

Time frame:
From Baseline (Week 0), Week 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV (up to Week 295), and Safety follow-up (up to Week 295)
Reported as:
Median · percent change
Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy
percent changeLevetiracetam: Adjunctive Therapy
Week 835.53 (-137.9 to 100.0)
Week 1059.39 (-138.2 to 100.0)
Week 1250.90 (-167.8 to 100.0)
Week 1560.29 (-129.4 to 100.0)
Week 1882.74 (-22.3 to 100.0)
Week 2180.33 (-44.1 to 100.0)
Week 2488.44 (-97.8 to 100.0)
Week 2793.84 (-4.8 to 100.0)
Week 3098.05 (-4.8 to 100.0)
Week 36100.00 (-94.5 to 100.0)
Week 4898.70 (-28.4 to 100.0)
Week 60100.00 (44.7 to 100.0)
Week 72100.00 (32.0 to 100.0)
Week 84100.00 (62.9 to 100.0)
Week 9699.57 (78.2 to 100.0)
Week 108100.00 (-48.0 to 100.0)
Week 120100.00 (80.4 to 100.0)
Week 132100.00 (50.7 to 100.0)
Week 144100.00 (93.4 to 100.0)
Week 15699.76 (93.5 to 100.0)
Week 16899.74 (90.7 to 100.0)
Week 18099.02 (86.1 to 100.0)
Week 19299.76 (85.5 to 100.0)
Week 20497.94 (78.3 to 100.0)
Week 21696.58 (81.4 to 100.0)
Week 22897.12 (96.6 to 100.0)
Week 24096.36 (86.8 to 100.0)
Week 25291.12 (85.3 to 96.9)
Week 26496.91 (95.8 to 98.0)
Week 27696.40 (95.2 to 97.6)
Week 28896.14 (94.2 to 98.0)
Week 30089.7 (89.7 to 89.7)
EOS/EDV21.86 (-120.1 to 100.0)
Safety Follow Up39.82 (-267.8 to 100.0)
SecondaryPercentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy

Percent difference in PSF per week on adjunctive therapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PSF per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. Positive value in percent difference from Baseline indicates reduction in PSF from Baseline. The mapping of seizure data to Analysis Visits was based on target dates of visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to next Analysis Visit (n+1).

Time frame:
From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV Week 2, EOS/EDV Week 4, and Safety follow-up (up to Week 295)
Reported as:
Number · percentage of participants
Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy
percentage of participantsLevetiracetam: Adjunctive Therapy
Week 2: <0%43.8
Week 2: 0% - <25%18.8
Week 2: 25% - <50%9.4
Week 2: ≥ 50%28.1
Week 2: ≥ 75%12.5
Week 2: 100%9.4
Week 4: <0%37.5
Week 4: 0% - <25%18.8
Week 4: 25% - <50%15.6
Week 4: ≥ 50%28.1
Week 4: ≥ 75%18.8
Week 4: 100%9.4
Week 6: <0%31.3
Week 6: 0% - <25%15.6
Week 6: 25% - <50%12.5
Week 6: ≥ 50%28.1
Week 6: ≥ 75%18.8
Week 6: 100%15.6
Week 8: <0%21.4
Week 8: 0% - <25%14.3
Week 8: 25% - <50%17.9
Week 8: ≥ 50%35.7
Week 8: ≥ 75%25.0
Week 8: 100%17.9
Week 10: <0%24.0
Week 10: 0% - <25%12.0
Week 10: 25% - <50%8.0
Week 10: ≥ 50%52.0
Week 10: ≥ 75%28.0
Week 10: 100%20.0
Week 12: <0%20.8
Week 12: 0% - <25%4.2
Week 12: 25% - <50%20.8
Week 12: ≥ 50%45.8
Week 12: ≥ 75%37.5
Week 12: 100%25.0
Week 15: <0%13.6
Week 15: 0% - <25%9.1
Week 15: 25% - <50%13.6
Week 15: ≥ 50%63.6
Week 15: ≥ 75%36.4
Week 15: 100%27.3
Week 18: <0%9.1
Week 18: 0% - <25%4.5
Week 18: 25% - <50%9.1
Week 18: ≥ 50%68.2
Week 18: ≥ 75%54.5
Week 18: 100%31.8
Week 21: <0%10.0
Week 21: 0% - <25%5.0
Week 21: 25% - <50%5.0
Week 21: ≥ 50%80.0
Week 21: ≥ 75%55.0
Week 21: 100%30.0
Week 24: <0%10.0
Week 24: 0% - <25%10.0
Week 24: 25% - <50%5.0
Week 24: ≥ 50%70.0
Week 24: ≥ 75%55.0
Week 24: 100%40.0
Week 27: <0%5.3
Week 27: 0% - <25%5.3
Week 27: 25% - <50%10.5
Week 27: ≥ 50%73.7
Week 27: ≥ 75%52.6
Week 27: 100%36.8
Week 30: <0%5.6
Week 30: 0% - <25%11.1
Week 30: 25% - <50%5.6
Week 30: ≥ 50%72.2
Week 30: ≥ 75%55.6
Week 30: 100%44.4
Week 36: <0%11.8
Week 36: 0% - <25%5.9
Week 36: 25% - <50%0
Week 36: ≥ 50%76.5
Week 36: ≥ 75%70.6
Week 36: 100%52.9
Week 48: <0%6.3
Week 48: 0% - <25%12.5
Week 48: 25% - <50%6.3
Week 48: ≥ 50%75.0
Week 48: ≥ 75%75.0
Week 48:100%43.8
Week 60: <0%0
Week 60: 0% - <25%0
Week 60: 25% - <50%6.3
Week 60: ≥ 50%75.0
Week 60: ≥ 75%68.8
Week 60: 100%43.8
Week 72: <0%0
Week 72: 0% - <25%0
Week 72: 25% - <50%7.7
Week 72: ≥ 50%92.3
Week 72: ≥ 75%76.9
Week 72: 100%53.8
Week 84: <0%0
Week 84: 0% - <25%0
Week 84: 25% - <50%0
Week 84: ≥ 50%100
Week 84: ≥ 75%84.6
Week 84: 100%53.8
Week 96: <0%0
Week 96: 0% - <25%0
Week 96: 25% - <50%0
Week 96: ≥ 50%92.3
Week 96: ≥ 75%92.3
Week 96: 100%46.2
Week 108: <0%8.3
Week 108: 0% - <25%0
Week 108: 25% - <50%0
Week 108: ≥ 50%83.3
Week 108: ≥ 75%75.0
Week 108: 100%50.0
Week 120: <0%0
Week 120: 0% - <25%0
Week 120: 25% - <50%0
Week 120: ≥ 50%90.9
Week 120: ≥ 75%90.9
Week 120: 100%63.6
Week 132: <0%0
Week 132: 0% - <25%0
Week 132: 25% - <50%0
Week 132: ≥ 50%80.0
Week 132: ≥ 75%70.0
Week 132: 100%50.0
Week 144: <0%0
Week 144: 0% - <25%0
Week 144: 25% - <50%0
Week 144: ≥ 50%87.5
Week 144: ≥ 75%87.5
Week 144: 100%50.0
Week 156: <0%0
Week 156: 0% - <25%0
Week 156: 25% - <50%0
Week 156: ≥ 50%85.7
Week 156: ≥ 75%85.7
Week 156: 100%42.9
Week 168: <0%0
Week 168: 0% - <25%0
Week 168: 25% - <50%0
Week 168: ≥ 50%100
Week 168: ≥ 75%100
Week 168: 100%50.0
Week 180: <0%0
Week 180: 0% - <25%0
Week 180: 25% - <50%0
Week 180: ≥ 50%100
Week 180: ≥ 75%100
Week 180: 100%50.0
Week 192: <0%0
Week 192: 0% - <25%0
Week 192: 25% - <50%0
Week 192: ≥ 50%100
Week 192: ≥ 75%100
Week 192: 100%50.0
Week 204: <0%0
Week 204: 0% - <25%0
Week 204: 25% - <50%0
Week 204: ≥ 50%83.3
Week 204: ≥ 75%83.3
Week 204: 100%16.7
Week 216: <0%0
Week 216: 0% - <25%0
Week 216: 25% - <50%0
Week 216: ≥ 50%100
Week 216: ≥ 75%100
Week 216: 100%20.0
Week 228: <0%0
Week 228: 0% - <25%0
Week 228: 25% - <50%0
Week 228: ≥ 50%60.0
Week 228: ≥ 75%60.0
Week 228: 100%20.0
Week 240: <0%0
Week 240: 0% - <25%0
Week 240: 25% - <50%0
Week 240: ≥ 50%100
Week 240: ≥ 75%100
Week 240: 100%33.3
Week 252: <0%0
Week 252: 0% - <25%0
Week 252: 25% - <50%0
Week 252: ≥ 50%66.7
Week 252: ≥ 75%66.7
Week 252: 100%0
Week 264: <0%0
Week 264: 0% - <25%0
Week 264: 25% - <50%0
Week 264: ≥ 50%100
Week 264: ≥ 75%100
Week 264: 100%0
Week 276: <0%0
Week 276: 0% - <25%0
Week 276: 25% - <50%0
Week 276: ≥ 50%100
Week 276: ≥ 75%100
Week 276: 100%0
Week 288: <0%0
Week 288: 0% - <25%0
Week 288: 25% - <50%0
Week 288: ≥ 50%100
Week 288: ≥ 75%100
Week 288: 100%0
Week 300: <0%0
Week 300: 0% - <25%0
Week 300: 25% - <50%0
Week 300: ≥ 50%50.0
Week 300: ≥ 75%50.0
Week 300: 100%0
EOS/EDV, Week 2: <0%3.1
EOS/EDV, Week 2: 0% - <25%3.1
EOS/EDV, Week 2: 25% - <50%0
EOS/EDV, Week 2: ≥ 50%3.1
EOS/EDV, Week 2: ≥ 75%3.1
EOS/EDV, Week 2: 100%3.1
EOS/EDV, Week 4: <0%20.0
EOS/EDV, Week 4: 0% - <25%10.0
EOS/EDV, Week 4: 25% - <50%20.0
EOS/EDV, Week 4: ≥ 50%20.0
EOS/EDV, Week 4: ≥ 75%10.0
EOS/EDV, Week 4: 100%0
Safety Follow Up: <0%37.5
Safety Follow Up: 0% - <25%4.2
Safety Follow Up: 25% - <50%12.5
Safety Follow Up: ≥ 50%45.8
Safety Follow Up: ≥ 75%29.2
Safety Follow Up: 100%20.8
SecondaryPercent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy

The percent difference in partial seizure frequency per week on monotherapy at Baseline and each analysis visit was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at analysis visit X)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. The maximum duration of study participation in monotherapy participants was shorter than in adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.

Time frame:
From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295)
Reported as:
Median · percent change
Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy
percent changeLevetiracetam: Monotherapy
Week 2-51.87 (-731.6 to 100.0)
Week 44.88 (-115.9 to 100.0)
Week 651.10 (-325.0 to 100.0)
Week 8100.00 (-1.1 to 100.0)
Week 10100.00 (-277.1 to 100.0)
Week 1276.92 (-10.0 to 100.0)
Week 15100.00 (-78.1 to 100.0)
Week 1891.58 (58.1 to 100.0)
Week 21100.00 (76.9 to 100.0)
Week 24100.00 (92.3 to 100.0)
Week 27100.00 (26.7 to 100.0)
Week 30100.00 (37.1 to 100.0)
Week 36100.00 (16.2 to 100.0)
Week 4898.08 (-138.3 to 100.0)
Week 6094.23 (-41.4 to 100.0)
Week 7292.31 (-36.2 to 100.0)
Week 8495.79 (-86.0 to 100.0)
Week 9698.08 (-65.0 to 100.0)
Week 10896.15 (-44.0 to 100.0)
Week 12093.68 (-46.7 to 100.0)
Week 13292.63 (-138.3 to 100.0)
Week 14492.63 (-106.9 to 100.0)
Week 15694.73 (8.3 to 100.0)
Week 168100.00 (-70.2 to 100.0)
Week 180100.00 (-274.5 to 100.0)
Week 192100.00 (-223.0 to 100.0)
Week 204100.00 (100.0 to 100.0)
Week 216100.00 (100.0 to 100.0)
Week 228100.00 (100.0 to 100.0)
Week 240100.00 (100.00 to 100.00)
Week 252100.00 (100.00 to 100.00)
Week 264100.00 (100.00 to 100.00)
Week 276100.00 (100.00 to 100.00)
Safety Follow Up100.0 (100.0 to 100.0)
SecondaryPercentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy

Percent difference in PSF per week on monotherapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PFS per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. Maximum duration of study participation in monotherapy participants was shorter than adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.

Time frame:
From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295)
Reported as:
Number · percentage of participants
Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy
percentage of participantsLevetiracetam: Monotherapy
Week 2: <0%60.0
Week 2: 0% - <25%0
Week 2: 25% - <50%20.0
Week 2: ≥ 50%40.0
Week 2: ≥ 75%20.0
Week 2: 100%20.0
Week 4: <0%50.0
Week 4: 0% - <25%0
Week 4: 25% - <50%16.7
Week 4: ≥ 50%33.3
Week 4: ≥ 75%33.3
Week 4: 100%33.3
Week 6: <0%33.3
Week 6: 0% - <25%0
Week 6: 25% - <50%16.7
Week 6: ≥ 50%50.0
Week 6: ≥ 75%33.3
Week 6: 100%16.7
Week 8: <0%16.7
Week 8: 0% - <25%16.7
Week 8: 25% - <50%0
Week 8: ≥ 50%50.0
Week 8: ≥ 75%50.0
Week 8: 100%50.0
Week 10: <0%20.0
Week 10: 0% - <25%0
Week 10: 25% - <50%0
Week 10: ≥ 50%80.0
Week 10: ≥ 75%80.0
Week 10: 100%60.0
Week 12: <0%20.0
Week 12: 0% - <25%0
Week 12: 25% - <50%20.0
Week 12: ≥ 50%60.0
Week 12: ≥ 75%60.0
Week 12: 100%40.0
Week 15: <0%20.0
Week 15: 0% - <25%0
Week 15: 25% - <50%20.0
Week 15: ≥ 50%60.0
Week 15: ≥ 75%60.0
Week 15: 100%60.0
Week 18: <0%0
Week 18: 0% - <25%0
Week 18: 25% - <50%0
Week 18: ≥ 50%100
Week 18: ≥ 75%80.0
Week 18: 100%40.0
Week 21: <0%0
Week 21: 0% - <25%0
Week 21: 25% - <50%0
Week 21: ≥ 50%100
Week 21: ≥ 75%100
Week 21: 100%60.0
Week 24: <0%0
Week 24: 0% - <25%0
Week 24: 25% - <50%0
Week 24: ≥ 50%100
Week 24: ≥ 75%100
Week 24: 100%80.0
Week 27: <0%0
Week 27: 0% - <25%0
Week 27: 25% - <50%20.0
Week 27: ≥ 50%80.0
Week 27: ≥ 75%80.0
Week 27: 100%80.0
Week 30: <0%0
Week 30: 0% - <25%0
Week 30: 25% - <50%20.0
Week 30: ≥ 50%80.0
Week 30: ≥ 75%60.0
Week 30: 100%60.0
Week 36: <0%0
Week 36: 0% - <25%20.0
Week 36: 25% - <50%0
Week 36: ≥ 50%80.0
Week 36: ≥ 75%80.0
Week 36: 100%60.0
Week 48: <0%20.0
Week 48: 0% - <25%0
Week 48: 25% - <50%0
Week 48: ≥ 50%80.0
Week 48: ≥ 75%80.0
Week 48:100%40.0
Week 60: <0%20.0
Week 60: 0% - <25%0
Week 60: 25% - <50%0
Week 60: ≥ 50%80.0
Week 60: ≥ 75%80.0
Week 60: 100%40.0
Week 72: <0%20.0
Week 72: 0% - <25%0
Week 72: 25% - <50%0
Week 72: ≥ 50%80.0
Week 72: ≥ 75%80.0
Week 72: 100%40.0
Week 84: <0%20.0
Week 84: 0% - <25%0
Week 84: 25% - <50%0
Week 84: ≥ 50%80.0
Week 84: ≥ 75%80.0
Week 84: 100%40.0
Week 96: <0%20.0
Week 96: 0% - <25%0
Week 96: 25% - <50%0
Week 96: ≥ 50%80.0
Week 96: ≥ 75%80.0
Week 96: 100%40.0
Week 108: <0%20.0
Week 108: 0% - <25%0
Week 108: 25% - <50%0
Week 108: ≥ 50%80.0
Week 108: ≥ 75%80.0
Week 108: 100%40.0
Week 120: <0%20.0
Week 120: 0% - <25%0
Week 120: 25% - <50%0
Week 120: ≥ 50%80.0
Week 120: ≥ 75%80.0
Week 120: 100%40.0
Week 132: <0%20.0
Week 132: 0% - <25%0
Week 132: 25% - <50%0
Week 132: ≥ 50%60.0
Week 132: ≥ 75%60.0
Week 132: 100%40.0
Week 144: <0%25.0
Week 144: 0% - <25%0
Week 144: 25% - <50%0
Week 144: ≥ 50%75.0
Week 144: ≥ 75%75.0
Week 144: 100%50.0
Week 156: <0%0
Week 156: 0% - <25%25.0
Week 156: 25% - <50%0
Week 156: ≥ 50%75.0
Week 156: ≥ 75%75.0
Week 156: 100%50.0
Week 168: <0%25.0
Week 168: 0% - <25%0
Week 168: 25% - <50%0
Week 168: ≥ 50%75.0
Week 168: ≥ 75%75.0
Week 168: 100%75.0
Week 180: <0%25.0
Week 180: 0% - <25%0
Week 180: 25% - <50%0
Week 180: ≥ 50%50.0
Week 180: ≥ 75%50.0
Week 180: 100%50.0
Week 192: <0%33.3
Week 192: 0% - <25%0
Week 192: 25% - <50%0
Week 192: ≥ 50%66.7
Week 192: ≥ 75%66.7
Week 192: 100%66.7
Week 204: <0%0
Week 204: 0% - <25%0
Week 204: 25% - <50%0
Week 204: ≥ 50%66.7
Week 204: ≥ 75%66.7
Week 204: 100%66.7
Week 216: <0%0
Week 216: 0% - <25%0
Week 216: 25% - <50%0
Week 216: ≥ 50%100
Week 216: ≥ 75%100
Week 216: 100%100
Week 228: <0%0
Week 228: 0% - <25%0
Week 228: 25% - <50%0
Week 228: ≥ 50%50.0
Week 228: ≥ 75%50.0
Week 228: 100%50.0
Week 240: <0%0
Week 240: 0% - <25%0
Week 240: 25% - <50%0
Week 240: ≥ 50%100
Week 240: ≥ 75%100
Week 240: 100%100
Week 252: <0%0
Week 252: 0% - <25%0
Week 252: 25% - <50%0
Week 252: ≥ 50%100
Week 252: ≥ 75%100
Week 252: 100%100
Week 264: <0%0
Week 264: 0% - <25%0
Week 264: 25% - <50%0
Week 264: ≥ 50%100
Week 264: ≥ 75%100
Week 264: 100%100
Week 276: <0%0
Week 276: 0% - <25%0
Week 276: 25% - <50%0
Week 276: ≥ 50%100
Week 276: ≥ 75%100
Week 276: 100%100
Safety Follow Up: <0%0
Safety Follow Up: 0% - <25%0
Safety Follow Up: 25% - <50%0
Safety Follow Up: ≥ 50%100
Safety Follow Up: ≥ 75%100
Safety Follow Up: 100%100
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation Participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The treatment-emergent adverse events (TEAEs) were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.

Time frame:
From Baseline (Week 0) to Visit 6 (up to Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period
percentage of participantsLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period62.50
SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period

A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.

Time frame:
From Baseline (Week 0) to Visit 6 (up to Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period
percentage of participantsLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period9.40
SecondaryPercentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period

An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.

Time frame:
From Baseline (Week 0) to Visit 6 (up to Week 6)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period
percentage of participantsLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period6.30
SecondaryPercentage of Participants With TEAEs During the Combined First and Second Period

An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.

Time frame:
From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs During the Combined First and Second Period
percentage of participantsLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
Percentage of Participants With TEAEs During the Combined First and Second Period96.9100
SecondaryPercentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period

A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.

Time frame:
From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period
percentage of participantsLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period56.333.3
SecondaryPercentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period

An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.

Time frame:
From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period
percentage of participantsLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period9.416.7

Adverse events

Collected over From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam: Adjunctive Therapy0/32 (0%)18/32 (56.3%)28/32 (87.5%)
Levetiracetam: Monotherapy0/6 (0%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
GastroenteritisInfections and infestations1/321/6
EpilepsyNervous system disorders2/321/6
Seizure clusterNervous system disorders2/321/6
PyrexiaGeneral disorders0/321/6
InfluenzaInfections and infestations0/321/6
Pneumonia bacterialInfections and infestations0/321/6
Pneumonia viralInfections and infestations3/320/6
Status epilepticusNervous system disorders3/320/6
Infantile spasmsNervous system disorders3/320/6
BronchitisInfections and infestations2/320/6
Most frequent other events
Showing 10 of 56
Most frequent other events
EventLevetiracetam: Adjunctive TherapyLevetiracetam: Monotherapy
NasopharyngitisInfections and infestations17/325/6
Hand-foot-and-mouth diseaseInfections and infestations3/323/6
EpistaxisRespiratory, thoracic and mediastinal disorders1/323/6
PyrexiaGeneral disorders12/322/6
Conjunctivitis allergicEye disorders3/322/6
GastroenteritisInfections and infestations7/322/6
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders3/322/6
Rhinitis allergicRespiratory, thoracic and mediastinal disorders3/322/6
EczemaSkin and subcutaneous tissue disorders9/321/6
DiarrhoeaGastrointestinal disorders8/320/6

Baseline characteristics

Baseline Characteristics refer to the SS_A and SS_M. The SS_A consisted of all enrolled participants on adjunctive therapy who received at least 1 dose of study medication in the evaluation period. The SS_M consisted of all enrolled participants on monotherapy who received at least 1 dose of study medication in the evaluation period.

Age, Continuous
Age, Continuous(Years)Levetiracetam: Adjunctive TherapyLevetiracetam: MonotherapyTotal
Mean14.7 ± 10.732.4 ± 13.217.5 ± 12.7
Age, Customized
Age, Customized(Participants)Levetiracetam: Adjunctive TherapyLevetiracetam: MonotherapyTotal
28 days - <24 months26329
24 months - <12 years639
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam: Adjunctive TherapyLevetiracetam: MonotherapyTotal
Female15520
Male17118
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Levetiracetam: Adjunctive TherapyLevetiracetam: MonotherapyTotal
Asian32638
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Levetiracetam: Adjunctive TherapyLevetiracetam: MonotherapyTotal
Japan32638
08

Study locations

21 sites
  • Ep0100 15
    Fukuoka, Japan
  • EP0100 3
    Hamamatsu, Japan
  • EP0100 6
    Izumi, Japan
  • Ep0100 20
    Kobe, Japan
  • EP0100 2
    Kodaira, Japan
  • Ep0100 21
    Kofu, Japan
  • EP0100 7
    Koshi, Japan
  • EP0100 9
    Nagakute, Japan
  • EP0100 5
    Niigata, Japan
  • Ep0100 12
    OBU, Japan
  • Ep0100 14
    Okayama, Japan
  • Ep0100 11
    Omura, Japan
  • Ep0100 13
    Osaka, Japan
  • Ep0100 18
    Saitama, Japan
  • EP0100 4
    Sapporo, Japan
  • Ep0100 10
    Sendai, Japan
  • Ep0100 19
    Sendai, Japan
  • Ep0100 16
    Shinjuku-ku, Japan
  • Ep0100 17
    Shinjuku-ku, Japan
  • EP0100 1
    Shizuoka, Japan
  • Ep0100 22
    Toyoake, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jun 2021, 42 months.

Results were first posted in Jul 2024, 3 years 1 month after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's 42 months is below that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 13, 2017
StartActual
Nov 30, 2017
Primary completionActual
Jun 1, 2021
CompletionActual
Jul 28, 2023
Results first posted
Jul 23, 2024
Last update
Jul 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03340064
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Nov 30, 2017
Primary completion
Jun 1, 2021
Completion
Jul 28, 2023
Results posted
Jul 23, 2024
Last update
Jul 23, 2024

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion